Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Prospective, Randomised, Controlled Phase 2 Study Investigating the Haemostatic Efficacy and Safety of Fibrinogen Concentrate (Octafibrin) and Cryoprecipitate as Fibrinogen Supplementation Sources in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei

Next Previous
Trial Profile

Prospective, Randomised, Controlled Phase 2 Study Investigating the Haemostatic Efficacy and Safety of Fibrinogen Concentrate (Octafibrin) and Cryoprecipitate as Fibrinogen Supplementation Sources in Patients Undergoing Cytoreductive Surgery for Pseudomyxoma Peritonei

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 09 Nov 2020

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Fibrinogen (Primary) ; Fibrinogen
  • Indications Surgical blood loss
  • Focus Registrational; Therapeutic Use
  • Acronyms FORMA-05
  • Sponsors Octapharma

    • Most Recent Events

    • 05 Oct 2020 Results (n=45) of sub-analysis assessing intra-operative and postoperative coagulation profiles presented at the ANESTHESIOLOGY 2020 Annual Meeting of the American Society of Anesthesiologists
    • 05 Nov 2019 According to an Octapharma media release, the human fibrinogen concentrate fibryga has received approval for use in treatment of acquired fibrinogen deficiency (AFD) in 15 European countries. The approval extends the market authorisation for fibryga, which is already approved for use in patients with congenital fibrinogen deficiency.The approval of fibryga for use in AFD is based on results of this clinical (FORMA-05) study.
    • 05 Nov 2019 According to Octapharma media release, results from this trial were discussed at American Society of Anesthesiologists Annual Meeting
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top